Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in RGS?
Regeneus Ltd: THE INVESTMENT CASE

Regeneus: Access latest PPT from Proactive's CEO Sessions

John Martin discussed regenerative medicine with investors.
Regeneus: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: RGS The Big Picture
John Martin, chief executive officer, Regeneus

Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.

The company provides exposure to the rapid growth global regenerative medicine market, utlising its world-calss stem cell and immuno-oncology technology platforms.

Its technology has been validated by positive pre-clinical and clinical data, and by a collaboration with a leading biopharma manufacturer in Japan.
 

ACCESS THE FULL PRESENTATION HERE

View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
Patient undergoing radiotherapy
August 02 2017
Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use